RET (V738A)

RET · Variant type: point · HGVS: p.V738A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	99.9%	0.1%	93.43
2	Selpercatinib	98.9%	1.1%	96.72
3	Gilteritinib	98.6%	1.4%	88.97
4	Vandetanib	94.3%	5.7%	95.74
5	Tivozanib	94.3%	5.7%	92.42
6	Sorafenib	93.3%	6.7%	96.72
7	Alpelisib	90.5%	9.5%	97.22
8	Entrectinib	90.2%	9.8%	93.69
9	Tenalisib	89.7%	10.3%	97.98
10	Sunitinib	89.5%	10.5%	91.73
11	Fedratinib	88.8%	11.2%	96.21
12	Defactinib	85.5%	14.5%	92.68
13	Ripretinib	83.4%	16.6%	92.95
14	Repotrectinib	71.5%	28.5%	84.21
15	Pacritinib	66.8%	33.2%	88.64
16	Erdafitinib	64.7%	35.3%	95.71
17	Avapritinib	53.2%	46.8%	97.73
18	Futibatinib	50.2%	49.8%	98.48
19	Apatinib	42.4%	57.6%	97.73
20	Canertinib	37.2%	62.8%	96.49
21	Quizartinib	32.6%	67.4%	99.50
22	Umbralisib	16.6%	83.4%	98.74
23	Idelalisib	12.7%	87.3%	100.00
24	Neratinib	12.1%	87.9%	93.18
25	Lazertinib	9.5%	90.5%	97.47

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	99.9%	100.0%	-0.1%
Selpercatinib	98.9%	100.0%	-1.1%
Gilteritinib	98.6%	100.0%	-1.4%
Vandetanib	94.3%	98.6%	-4.2%
Tivozanib	94.3%	99.7%	-5.4%
Sorafenib	93.3%	94.0%	-0.7%
Alpelisib	90.5%	99.6%	-9.1%
Entrectinib	90.2%	99.6%	-9.4%
Tenalisib	89.7%	98.5%	-8.8%
Sunitinib	89.5%	97.2%	-7.7%
Fedratinib	88.8%	99.9%	-11.1%
Defactinib	85.5%	—	—
Ripretinib	83.4%	—	—
Repotrectinib	71.5%	—	—
Pacritinib	66.8%	—	—
Erdafitinib	64.7%	94.7%	-30.0%
Avapritinib	53.2%	—	—
Futibatinib	50.2%	97.7%	-47.5%
Apatinib	42.4%	—	—
Canertinib	37.2%	—	—
Quizartinib	32.6%	—	—
Umbralisib	16.6%	—	—
Idelalisib	12.7%	—	—
Neratinib	12.1%	—	—
Lazertinib	9.5%	—	—

Cancer	Organ	Source
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.6ms